Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Buy
62
PI Quote, Financials, Valuation and Earnings
Last price:
$123.38
Seasonality move
:
14.98%
Day range:
$121.02 - $124.31
52-week range:
$60.85 - $239.88
Dividend yield:
0%
P/E ratio:
56.67x
P/S ratio:
9.85x
P/B ratio:
22.26x
Volume:
394.7K
Avg. volume:
856.7K
1-year change:
-28.88%
Market cap:
$3.6B
Revenue:
$366.1M
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingImpinj has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $123.50, Impinj has an estimated upside of 0.15% from its current price of $123.32.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing 100% downside risk from its current price of $123.32.
Fair Value
-
According to the consensus of 5 analysts, Impinj has 0.15% upside to fair value with a price target of $123.50 per share.
PI vs. S&P 500
-
Over the past 5 trading days, Impinj has overperformed the S&P 500 by 8.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Impinj does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Impinj revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Impinj reported revenues of $74.3M.
Earnings Growth
-
Impinj has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Impinj reported earnings per share of -$0.30.
Enterprise value:
3.7B
EV / Invested capital:
8.35x
Price / LTM sales:
9.85x
EV / EBIT:
1,722.46x
EV / Revenue:
10.21x
PEG ratio (5yr expected):
--
EV / Free cash flow:
83.84x
Price / Operating cash flow:
80.94x
Enterprise value / EBITDA:
241.64x
Gross Profit (TTM):
$188M
Return On Assets:
-0.21%
Net Income Margin (TTM):
-0.26%
Return On Equity:
-0.74%
Return On Invested Capital:
-0.23%
Operating Margin:
-12.88%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $290.6M | $298.5M | $363.5M | $76.8M | $74.3M | |
| Gross Profit | $152.6M | $146M | $188M | $37.5M | $36.7M | |
| Operating Income | -$14.7M | -$49M | -$4.9M | -$9.9M | -$9.6M | |
| EBITDA | -$8.4M | $12.9M | $15.4M | $38.1M | -$4.4M | |
| Diluted EPS | -$0.71 | -$0.35 | -$0.04 | $1.10 | -$0.30 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $173.7M | $242.6M | $305.2M | $324.4M | $308.6M | |
| Total Assets | $214.5M | $316.9M | $372.7M | $413.9M | $479.8M | |
| Current Liabilities | $112.2M | $32.6M | $54.6M | $34.4M | $28.2M | |
| Total Liabilities | $128.1M | $323.2M | $346M | $328M | $319.3M | |
| Total Equity | $86.4M | -$6.3M | $26.6M | $85.9M | $160.6M | |
| Total Debt | $85.2M | $288.7M | $280.6M | $282.3M | $283.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.1M | $37.3M | $57M | $60.1M | -$11.1M | |
| Cash From Investing | -$12.7M | $80.9M | -$176.4M | $5M | $21.2M | |
| Cash From Financing | -$2.2M | $11.1M | $13.8M | $6.9M | $5.1M | |
| Free Cash Flow | -$27.7M | $19.9M | $44.3M | $53.9M | -$13M | |
PI
Sector
Market Cap
$3.6B
$80M
Price % of 52-Week High
51.41%
62.02%
Dividend Yield
0%
0%
Shareholder Yield
--
0.9%
1-Year Price Total Return
-28.88%
-14.14%
Beta (5-Year)
1.644
0.841
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$115.40
200-day SMA
Sell
Level
$145.76
Bollinger Bands (100)
Buy
Level
81.69 - 132.81
Chaikin Money Flow
Sell
Level
-10.9M
20-day SMA
Buy
Level
$100.74
Relative Strength Index (RSI14)
Buy
Level
76.80
ADX Line
Buy
Level
41.19
Williams %R
Sell
Level
-7.2235
50-day SMA
Buy
Level
$89.91
MACD (12, 26)
Buy
Level
10.42
25-day Aroon Oscillator
Buy
Level
84
On Balance Volume
Neutral
Level
33.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.2444)
Sell
CA Score
(Annual)
Level (-0.9564)
Sell
Beneish M-Score
(Annual)
Level (-0.3432)
Sell
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.6156)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
Stock Forecast FAQ
In the current month, PI has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PI average analyst price target in the past 3 months is $123.50.
-
Where Will Impinj Stock Be In 1 Year?
According to analysts, the consensus estimate is that Impinj share price will rise to $123.50 per share over the next 12 months.
-
What Do Analysts Say About Impinj?
Analysts are divided on their view about Impinj share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Impinj is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Impinj's Price Target?
The price target for Impinj over the next 1-year time period is forecast to be $123.50 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Impinj is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PI?
You can purchase shares of Impinj via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Impinj shares.
-
What Is The Impinj Share Price Today?
Impinj was last trading at $123.38 per share. This represents the most recent stock quote for Impinj. Yesterday, Impinj closed at $123.32 per share.
-
How To Buy Impinj Stock Online?
In order to purchase Impinj stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Mobileye Might Be Wall Street’s Next Big Surprise
The trend to automate vehicles started long ago when adding…
Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
99
SOC alert for May 20
Sable Offshore [SOC] is up 14.35% over the past day.
Buy
52
RGC alert for May 20
Regencell Bioscience Holdings [RGC] is down 10.93% over the past day.
Sell
40
GWLIF alert for May 20
Great-West Lifeco [GWLIF] is down 10.31% over the past day.
